DEA's telemedicine special registration rule is under final review as flexibilities near their December 31 end

The federal rule that could replace DEA's temporary telemedicine flexibilities has moved a step closer. DEA's final rule on Special Registrations for Telemedicine and Limited State Telemedicine Registrations has been under White House regulatory review since August 25, 2026, and the current flexibilities still end on December 31, 2026. That's about ten weeks away. If you prescribe Schedule II–V medications by telemedicine, now is the time to plan for both outcomes.

This is an NP-facing briefing, not legal advice. The final rule's text has not been published, so nobody outside government can say yet exactly what it will require. What follows sticks to what the official records show.

What changed

The Office of Information and Regulatory Affairs (OIRA), part of the White House Office of Management and Budget, lists the DEA final rule (RIN 1117-AB40) as a pending regulatory review received August 25, 2026. The record lists the rule as economically significant and at the final rule stage. DEA's regulatory agenda entry lists the target for final action as November 2026.

OIRA review is usually one of the last steps before a major rule is published in the Federal Register. It does not mean the rule is final, and a target month in the agenda is not a deadline. Rules can clear review sooner, later, or with changes.

As of October 22, 2026, the Federal Register shows no fifth temporary extension and no published final special registration rule. OIRA is still holding stakeholder meetings on the rule, with another scheduled for November 2, 2026.

Where things stand today

Under the fourth temporary extension, DEA-registered practitioners may prescribe Schedule II–V controlled medications by telemedicine without a prior in-person medical evaluation, subject to the temporary rule's conditions. That rule is effective January 1 through December 31, 2026. We covered it in our earlier post on the fourth temporary rule.

DEA has said the temporary rules exist to prevent a "telemedicine cliff," meaning a sudden return to the pre-pandemic in-person requirement before a permanent framework is in place.

What the special registration would do

The final text is not public yet. The January 17, 2025 proposed rule proposed a special registration that would let practitioners, including mid-level practitioners such as NPs, prescribe controlled substances by audio-video telemedicine (and in limited cases by other modalities) without a prior in-person evaluation. Prescribers would have to follow added prescription, recordkeeping, and reporting requirements. The proposal also would have required certain direct-to-consumer telemedicine platforms to register with DEA. DEA received more than 6,400 comments, and its agenda says it is weighing alternatives, so the final rule may differ from the proposal.

Who this affects

NPs who prescribe controlled substances to patients they have not seen in person, including in behavioral health, addiction treatment, and primary care telehealth.
Clinics and telehealth companies whose protocols depend on the temporary flexibilities.
NPs who hold DEA registrations in more than one state, since the proposal also covered state-level telemedicine registrations.
Patients on ongoing telemedicine controlled-substance treatment who need continuity plans.

What NPs should do now

Inventory your exposure. List the patients and service lines where you prescribe Schedule II–V medications without a prior in-person visit.
Plan for two scenarios. One where a final rule (or another extension) arrives before December 31, and one where neither does and the in-person requirement returns on January 1, 2027.
Keep state law in view. Federal flexibility never overrides state APRN practice, telehealth, collaboration, or PDMP rules where the patient is located.
Check your DEA registrations. Confirm each one is current and matches the states where your patients are located.
Watch the official record. Track the OIRA review page, the Federal Register, and DEA press releases instead of relying on secondhand summaries.
Read the final text yourself once it publishes, especially the effective date and any transition period.

What this is not

Not a final rule. Nothing has changed for prescribers yet.
Not a prediction of the final rule's content or timing.
Not legal advice. Talk with your compliance team, counsel, or state board about your situation.

Sources

If you're juggling DEA registrations alongside state licenses and CE deadlines, CeMe Tracker and the State Data Hub can help you keep each state's requirements in one place. Always confirm prescribing authority against primary federal and state sources before changing a telemedicine protocol.